Retrieve available abstracts of 29 articles: HTML format
Single Articles
June 2025
JING Z, Zhao L, Mai Y, Sun P, et al Hematopoietic stem cell transplantation outcomes in pediatric acquired aplastic
anemia with inherited bone marrow failure syndrome-associated genes.
Bone Marrow Transplant. 2025 Jun 25. doi: 10.1038/s41409-025-02671. PubMed
ZHAO X, Zhang YP, Ye BD, Lu PH, et al Clinical outcomes of offspring and matched unrelated donor transplants in
relapsed or refractory severe aplastic anemia patients aged 40-50: a
retrospective analysis from the CBMTR over the past decade.
Bone Marrow Transplant. 2025 Jun 17. doi: 10.1038/s41409-025-02617. PubMed
May 2025
MONTORO J, Eikema DJ, Piepenbroek B, Tuffnell J, et al Donor impact on allogeneic transplant outcomes with PTCy for severe aplastic
anemia: a study of the SAAWP EBMT.
Bone Marrow Transplant. 2025 May 27. doi: 10.1038/s41409-025-02633. PubMedAbstract available
LIMERICK E, Hsieh MM, Barretto M, Jeffries N, et al Kidney function after nonmyeloablative hematopoietic cell transplant for sickle
cell disease.
Bone Marrow Transplant. 2025;60:690-696. PubMedAbstract available
April 2025
IBRAHIMOVA A, Khoury R, Jodele S, Grimley M, et al Abatacept for acute graft versus host disease prophylaxis in children with sickle
cell disease patients undergoing HLA identical sibling hematopoietic stem cell
transplantation.
Bone Marrow Transplant. 2025 Apr 29. doi: 10.1038/s41409-025-02601. PubMedAbstract available
GONZALEZ VICENT M, Pereto A, Zubicaray J, Molina B, et al Outcomes in allogeneic hematopoietic stem cell transplantation for Fanconi
anemia.
Bone Marrow Transplant. 2025 Apr 12. doi: 10.1038/s41409-025-02591. PubMed
LIU J, Mai Y, Jing Z, Zhao L, et al Protective factors, management and prognosis of mixed chimerism after allogeneic
hematopoietic stem cell transplantation for severe aplastic anemia in children.
Bone Marrow Transplant. 2025 Apr 6. doi: 10.1038/s41409-025-02577. PubMedAbstract available
March 2025
KLEINSCHMIDT K, Penkivech G, Troeger A, Foell J, et al alphass T-cell depleted haploidentical stem cell transplantation for pediatric and
young adult patients with transfusion-dependent thalassemia.
Bone Marrow Transplant. 2025 Mar 18. doi: 10.1038/s41409-025-02546. PubMedAbstract available
February 2025
LIN MH, Huang XJ, Xu LP, Wang Y, et al The haematopoietic cell transplantation comorbidity index predicts clinical
outcomes for severe aplastic anaemia patients after haploidentical haematopoietic
stem cell transplantation.
Bone Marrow Transplant. 2025 Feb 13. doi: 10.1038/s41409-025-02513. PubMedAbstract available
November 2024
GIAMMARCO S, Limongiello MA, Di Marino L, Metafuni E, et al The role of daratumumab in complications post-allogeneic hematopoietic stem cell
transplantation: a single-center prospective study on PRCA and AIHA.
Bone Marrow Transplant. 2024 Nov 20. doi: 10.1038/s41409-024-02479. PubMedAbstract available
September 2024
URIA-OFICIALDEGUI ML, Quintero V, Benitez-Carabante MI, Bueno D, et al Accurate donor and recipient selection and a short time to transplant offer
excellent outcomes in upfront hematopoietic stem cell transplantation from
matched unrelated donors for pediatric severe aplastic anemia and refractory
cytopenia of childhood.
Bone Marrow Transplant. 2024 Sep 3. doi: 10.1038/s41409-024-02406. PubMed
August 2024
LIU L, Han B, Zhang Y, Lei M, et al First-line treatment of severe aplastic anemia: immunosuppressive therapy plus
eltrombopag versus haploidentical hematopoietic stem cell transplantation, a
multicenter prospective study.
Bone Marrow Transplant. 2024 Aug 1. doi: 10.1038/s41409-024-02377. PubMedAbstract available
June 2024
GILMORE RM, Abernathy K, Shultes K, Eplin DD, et al Efficacy and safety of outpatient fludarabine, cyclophosphamide, and rituximab
based allogeneic hematopoietic cell transplantation in adults with severe
aplastic anemia.
Bone Marrow Transplant. 2024 Jun 15. doi: 10.1038/s41409-024-02323. PubMedAbstract available
LONGVAL T, Lepretre AC, Ravinet A, Fayard A, et al Efficacy and safety of Daratumumab for the treatment of ABO-incompatible pure red
cell aplasia after allogenic HSCT: report from SFGM-TC.
Bone Marrow Transplant. 2024;59:893-895. PubMed
May 2024
VASSEUR L, Cuffel A, Pondarre C, Dalle JH, et al Early lymphocyte reconstitution and viral infections in adolescents and adults
transplanted for sickle cell disease.
Bone Marrow Transplant. 2024;59:708-710. PubMed
April 2024
ZHANG X, Zhao X, Chen S, Hao M, et al Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for
allogeneic stem cell transplantation in aplastic anemia patients.
Bone Marrow Transplant. 2024 Apr 5. doi: 10.1038/s41409-024-02266. PubMedAbstract available
CIANGOLA G, Santinelli E, McLornan DP, Pagliuca S, et al Diagnostic evaluation in bone marrow failure disorders: what have we learnt to
help inform the transplant decision in 2024 and beyond?
Bone Marrow Transplant. 2024;59:444-450. PubMedAbstract available
March 2024
FURST S, Bernit E, Legrand F, Granata A, et al Durable engraftment after pharmacological pre-transplant immune suppression
followed by reduced-toxicity myeloablative haploidentical stem cell
transplantation in highly HLA-immunized adults with sickle cell disease.
Bone Marrow Transplant. 2024 Mar 14. doi: 10.1038/s41409-024-02257. PubMedAbstract available
JO T, Arai Y, Kitawaki T, Nakamura N, et al KyoTox-e score; prediction of post-CAR-T prolonged thrombocytopenia using
peripheral blood data before apheresis.
Bone Marrow Transplant. 2024;59:419-421. PubMed
February 2024
YAMAMOTO R, Hiramoto N, Fujimoto A, Yamazaki H, et al Impact of antithymocyte globulin usage and risk stratification for posttransplant
lymphoproliferative disorders in aplastic anemia patients after allogeneic
hematopoietic cell transplantation.
Bone Marrow Transplant. 2024 Feb 10. doi: 10.1038/s41409-024-02234. PubMed
MEISSNER B, Lang P, Bader P, Hoenig M, et al Finding a balance in reduced toxicity hematopoietic stem cell transplantation for
thalassemia: role of infused CD3+ cell count and immunosuppression.
Bone Marrow Transplant. 2024 Feb 7. doi: 10.1038/s41409-024-02219. PubMedAbstract available
January 2024
GREENMYER JR, Ariagno S, Ali A, Pence L, et al Autoimmune cytopenias following pediatric hematopoietic cell transplant.
Bone Marrow Transplant. 2024;59:117-120. PubMed
December 2023
GABELLI M, Perez-Martinez A, Bueno Sanchez D, Lucchini G, et al Abatacept treatment for autoimmune hemolytic anemia occurring post hematopoietic
stem cell transplantation.
Bone Marrow Transplant. 2023 Dec 14. doi: 10.1038/s41409-023-02173. PubMed
October 2023
AYAS M, Al-Hashim F, Siddiqui K, Al-Jefri A, et al Hematopoietic stem cell transplantation in patients with Fanconi anemia: a report
of late effects and psychosocial adjustment in life.
Bone Marrow Transplant. 2023 Oct 25. doi: 10.1038/s41409-023-02133. PubMed
CANCIO M, Troullioud Lucas AG, Bierings M, Klein E, et al Predictors of outcomes in hematopoietic cell transplantation for Fanconi anemia.
Bone Marrow Transplant. 2023 Oct 17. doi: 10.1038/s41409-023-02121. PubMedAbstract available
September 2023
SATTY AM, Klein E, Mauguen A, Kunvarjee B, et al T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment
of Fanconi anemia and MDS/AML.
Bone Marrow Transplant. 2023 Sep 29. doi: 10.1038/s41409-023-02113. PubMedAbstract available
August 2023
ROSSI M, Szepetowski S, Yakouben K, Paillard C, et al Recent results of hematopoietic stem cell transplantation for thalassemia with
busulfan-based conditioning regimen in France: improved thalassemia free survival
despite frequent mixed chimerism. A retrospective study from the Francophone
Society of St
Bone Marrow Transplant. 2023 Aug 4. doi: 10.1038/s41409-023-02079. PubMed
July 2023
XU ZL, Xu LP, Zhang YY, Cheng YF, et al Mixed chimaerism is associated with poorer long-term failure-free survival among
aplastic anaemia patients receiving HLA-matched donor transplantation.
Bone Marrow Transplant. 2023;58:832-834. PubMed
April 2023
GOMEZ-ARTEAGA A, Orfali N, Pasciolla M, Baptiste A, et al Haploidentical allogeneic stem cell transplantation with post-transplant
cyclophosphamide and subsequent kidney transplant for patients with severe sickle
cell disease with end-stage kidney disease (ESKD).
Bone Marrow Transplant. 2023 Apr 12. doi: 10.1038/s41409-023-01981. PubMed